Unravelling the Politics Behind India’s PM-JAY Health Insurance Scheme

By HEOR Staff Writer

July 26, 2023

The PM-JAY health insurance scheme, launched in India in 2018, was a crucial step towards universal health coverage (UHC). The policy’s design was shaped by a mix of technical and political elements, with a focus on bureaucratic aspects rather than ideological ones. The scheme was introduced by the ruling government just before national elections, leveraging policy legacies from previous and state insurance schemes. Key decisions such as the coverage amount and portability of benefits were centrally driven, while inputs from Indian states influenced features like the mode of implementation and provider network. This balanced approach facilitated the adoption of the reform. However, the scheme’s success hinges on addressing systemic issues and involving all stakeholders. As PM-JAY continues to be implemented, understanding the politics, power dynamics, and structural issues that shaped its formulation will be crucial.

Reference url

Recent Posts

pharmaceutical access initiative
Pharmaceutical Access Initiative Promotes Unified Health Systems in Europe

By João L. Carapinha

June 12, 2026

The pharmaceutical access initiative led by the Beneluxa countries urges EU and EEA Member States to pursue closer coordination on medicine affordability and supply security. By combining forces, nations can protect universal health systems that treat healthcare as a social right while still enco...
health economic security
Health Economic Security as a Pillar for Growth in Central and Eastern Europe

By HEOR Staff Writer

June 12, 2026

Central and Eastern European nations face intensifying demographic pressures, including rapid population aging, shrinking workforces, and heightened security risks that endanger long-term prosperity. In a recent EFPIA statement, health economic security is seen as essential, as targeted healthcar...
gene therapy reimbursement
Gene Therapy Reimbursement Strategies for Vision Restoration

By HEOR Staff Writer

June 12, 2026

Gene therapy reimbursement in the Netherlands has demonstrated clear clinical value since the 2021 conditional access agreement for voretigene neparvovec (Luxturna®). Five years of structured real-world use confirmed that carefully designed protocols successfully selected appropriate patients wit...